96results about How to "Low hemolytic" patented technology

The invention discloses a preparation method of a nano collagen membrane. The method includes the following steps of step one, dissolving collagen in hexafluoroisopropanol to obtain an 80-120mg / ml of collagen hexafluoroisopropanol solution; and step two, subjecting the collagen hexafluoroisopropanol solution obtained from the step one to electrostatic spinning with voltage of 15-19 KV, the receiving distance of 12.5-15cm and the advance speed of 0.5-1.2 ml / h so as to remove hexafluoroisopropanol to obtain the nano collagen membrane. The invention further discloses a preparation method of a double-layer collagen membrane, the prepared collagen membrane and application of the collagen membrane. The collagen membrane is excellent in mechanical property, free of cytotoxicity, low in hemolysis and antigenicity and high in biological activity.

The invention relates to a saponin with immune adjuvant function and a preparation method thereof, a vaccine preparation containing the saponin as an adjuvant, and applications of the saponin and the vaccine preparation in the prevention and treatment of infectious diseases and cancers of human and animals. The saponin is platycodin D, platycodin D2, or a total-saponin containing the two saponin compounds. The platycodin D and platycodin D2 are both extracted and separated from balloonflower, a Chinese medicine. The saponin can induce an organism to generate Th1-type and Th2-type immune responses, show the capability of inducing the organism to generate stronger cell immune response and humoral immune response to a vaccine than the alhydrogel adjuvant known in the prior art, and can be taken as the immune adjuvant for a plurality of vaccines and achieve an ideal immunity effect. The vaccine which takes the saponin as the adjuvant has simple preparation technology and simple and convenient method, and the quality is easy to control and the saponin can be reserved by freezing.

The invention discloses novel blank liposomes taking ginsenoside derivatives as membrane materials as well as a preparation method and application thereof. The ginsenoside derivatives used in the novel blank liposomes taking the ginsenoside derivatives as the membrane materials are high in activity and low in hemolytic activity, and can be used as liposome membrane materials for preparing blank liposomes; moreover, structures of some of the compounds are novel. In addition, the novel blank liposomes prepared by using the ginsenoside derivatives meet the requirements for hemolytic activity; andthus, the liposomes are higher in safety, better in film-forming properties and more excellent in stability. Therefore, the liposomes are of important application values.

The invention relates to an antibacterial and antiviral hybrid peptide as well as a preparation method and application thereof. An amino acid sequence and a nucleotide sequence of the antibacterial and antiviral hybrid peptide are as shown in SEQ ID No. 1 and 2. A gene for coding the antibacterial and antiviral hybrid peptide is cloned to an expression vector pPICZ[alpha]A to obtain a recombinant vector, then Pichia pastoris is converted, methyl alcohol is used for inducing expression, and an expression product is purified to obtain the target antibacterial antiviral hybrid peptide. The antibacterial and antiviral hybrid peptide can prevent and kill various bacteria and viruses, has low probability of resistance, and therefore, can serve as an ideal antibiotic substituent, a people and livestock biological antibacterial and antiviral medicine, a feed additive, a preservative, a sanitizer or the like.

The invention discloses a water-soluble florfenicol clathrate with high bioavailability. The water-soluble florfenicol clathrate is prepared from the following components in parts by weight: 5-15 parts of florfenicol or pharmaceutically acceptable salt of florfenicol, 20-60 parts of a florfenicol adsorption carrier, 1-2 parts of an absorption promoter, and 10-30 parts of a florfenicol cosolvent. For the florfenicol clathrate provided by the invention, the solubility of florfenicol is effectively improved, the bioavailability of florfenicol is improved, the hemolysis property of the medicine is alleviated, the release rate of the medicine is controlled, and the bad smell is masked. The preparation method provided by the invention comprises the following steps: firstly, mixing the florfenicol adsorption carrier, the absorption promoter and the florfenicol cosolvent, adding with florfenicol or the pharmaceutically acceptable salt of florfenicol under the water bath water control condition, carrying out stirring, carrying out heat preservation, and carrying out drying, thus obtaining the florfenicol clathrate. The technological operation is simple, the abundant time and manpower are saved, and during the preparation process, no organic solvents are used, so that the preparation method is safe and reliable and is free of pollution, and the process is simple and easy to realize.

The invention belongs to the field of pharmaceutic preparations, and discloses the preparation and pharmaceutical application of a protein adsorption-resistant photic sensitivity-enhanced anoxic stress cationic carrier. A cationic polymer is taken as a skeleton to modify a zwitter-ion glycine betaine monomer so as to weaken the adsorption to protein in an organism of the polymer; further modifyingthe intermediate with a hydrophobic connecting arm containing an anoxic stress azobenzene structure and a photosensitizer, so as to construct an amphipathic polymer carrier. The cationic modifier form a nanoparticle through self assembling in a water solution, can be directly applied to photodynamics therapy, can also be used for loading hydrophobic chemical drugs or nucleic acid drugs and applied to photodynamics and antineoplastic drug combination therapy. According to the invention, the photodynamics therapy of the photosensitizer is used for constructing a high-anoxic tumor microenvironment to stimulate nanometer disassembly, thus promoting drug release and improving the utilization ratio; in addition, through the sensitivity-enhanced antineoplastic drug therapeutic effect generated by the photodynamic active oxygen, the high-efficient synergistic treatment on tumour is realized.

The invention belongs to the field of antimicrobial peptides, and discloses an antimicrobial peptide based on a cell penetrating peptide Tat (49-57) and a synthetic method of the antimicrobial peptide. The antimicrobial peptide is Tat (YG), Tat (YY), Tat (FG) or Tat (FF), and a sequence of a peptide chain is successively as shown by SEQ ID No. 2 to No. 5. The antimicrobial peptide is synthesized by adopting Wang resin as a carrier, adopting Fmoc as an amino acid side chain protection base, adopting a DMF solution of piperidine as a deprotection reagent and adopting HBTU, HOBT and DIEA as amino acid condensing agents in a solid-phase synthetic method. The four derivative antimicrobial peptides have good inhibition efficiency for escherichia coli, salmonella typhimurium, Bacillus subtilis and staphylococcus aureus, and the inhibition rate for some bacteria can be higher than that of the cell penetrating peptide Tat (49-57); and moreover, the hemolytic activity of the four derivative microbial peptides is small, and the concentration when the bacteriostatic activity is played cannot reach the lowest hemolytic concentration.

The invention relates to an antibacterial peptide derivative from a forest frog and application thereof and belongs to the technical field of biochemical polypeptide medicines. The polypeptide is a small-molecule polypeptide which is designed artificially and synthesized chemically by taking a natural antimicrobial peptide from the skin secretion of a forest frog as a template. The polypeptide comprises 18 amino acid residues and has a sequence as shown in a sequence table. The molecular weight of the polypeptide is 2542.9Da, and the isoelectric point is 12.6. Experiments show that the small-molecule polypeptide has a broad-spectrum effect of killing a variety of bacteria and has no hemolytic activity in an antibacterial and anticancer concentration range, and the bacteria can not become resistant to the small-molecule polypeptide. In addition, Experiments on animals show that the polypeptide has the function of resisting wound infection. The polypeptide has a small molecular weight, can be synthesized artificially and conveniently, is a small-molecule polypeptide with quite high application value and can be used for preparing novel antimicrobial and antiinfectious medicines.

The invention provides niclosamide ethanolamine salt-hydroxypropyl-beta-cyclodextrin inclusion and a preparation method thereof; the inclusion is prepared from niclosamide ethanolamine salt and hydroxypropyl-beta-cyclodextrin as a raw material and belongs to the field of pharmacy. In the invention, a molar ratio of hydroxypropyl-beta-cyclodextrin to niclosamide ethanolamine salt is 7:(1-16):1, theinclusion is prepared by: adding niclosamide ethanolamine salt to a hydroxypropyl-beta-cyclodextrin solution prepared, stirring in the dark to obtain a clear solution, and lyophilizing to obtain theniclosamide ethanolamine salt-hydroxypropyl-beta-cyclodextrin inclusion; after the inclusion is formed, the water solubility of the niclosamide ethanolamine salt is obviously improved. The inclusion has high inclusion rate, the preparation method is simple, the efficiency is high, the application range is wide, and the inclusion is suitable for large-scale production.

The method for preparing high-pharmacodynamic low-hemolytic hypoglycosyl secondary dioscin or diosgenin by enzyme method to hydrolyze dioscin glycosyl includes the following steps: using the enzyme capable of hydrolyzing the dioscin glycosyl making the enzyme, dioscin and buffer solution be mixed and reacted for 4-40 hr., reaction temp. is 4-75 deg.C and pH value is 3-9 so as to obtain the low-glycosyl secondary dioscin or diosgenin.

The invention discloses a preparation method of a copper-containing carboxymethyl chitosan-sodium alginate support, which comprises the following steps: (1) preparing a nano-copper solution with ultrapure water; (2) preparing the carboxymethyl chitosan and sodium alginate are added to the nano-copper solution prepared in step (1), and mixed uniformly to obtain a mixed solution; (3) freeze-drying the mixed solution obtained in step (2) to obtain a freeze-dried initial scaffold; (4) Adding CaCl2 solution to the initial stent obtained in step (3) for cross-linking, washing to obtain a cross-linked stent; (5) lyophilizing the cross-linked stent obtained in step (4) to obtain the obtained Copper-containing carboxymethyl chitosan-sodium alginate antibacterial scaffold for bone repair. The copper-containing carboxymethyl chitosan-sodium alginate scaffold prepared by the preparation method of the invention has a porous structure and good biocompatibility and antibacterial effect.

The invention discloses novel antimicrobial peptide Hainanenin-5 of Amolops hainanensis, a gene of the antimicrobial peptide Hainanenin-5 of Amolops hainanensis, a separation method and a chemical synthesis method for the antimicrobial peptide Hainanenin-5 of Amolops hainanensis and application of the gene of the antimicrobial peptide Hainanenin-5 of Amolops hainanensis, and belongs to the technical field of biomedicine. The Hainanenin-5 is small peptide which is obtained by the steps of electrically stimulating the Amolops hainanensis so as to collect a skin exudate, centrifuging, freeze-drying, performing gel filtration column chromatography and reverse phase-high performance liquid chromatography (RP-HPLC) and purifying, and has a C terminal containing a seven-membered ring; the molecular weight is 2,337.91; and the isoelectric point is 10.11. A primary structure of the Hainanenin-5 is Phe<1>a<2>Leu<3>Gly<4>Ala<5>Val<6>Thr<7>Lys<8>Arg<9>Leu<10>Pro<11>Ser<12>Leu<13>Phe<14>Cys<15>Leu<16>Ile<17>Thr<18>Arg<19>Lys<20>Cys<21>. A gene for encoding a Hainanenin-5 precursor consists of 321 nucleotides, wherein a mature peptide part is encoded by 139th to 201st nucleotides. The Hainanenin-5 has low molecular weight and a simple structure, only contains one disulfide bond, and can be conveniently prepared through chemical synthesis and genetic engineering. The Hainanenin-5 is used for preparing a therapeutic medicine for pathogenic microorganism infectious diseases, has broad-spectrum antimicrobial activity, has the activities on gram-positive bacteria, gram-negative bacteria and fungi (including clinically separated medicine-resistant strains), and also has the advantages of low hemolysis.

The present invention discloses a salvianolic acid A injection preparation and the preparation method, the components are salvianolic acid A and pharmaceutical excipients, the present invention is characterized in that the pharmaceutical excipients are vitamin C, the weight ratio of the salvianolic acid A and the vitamin C is 16 to 25 :1, the preferential weight ratio of the salvianolic acid A and the vitamin C is 20:1; the toxicological experiments show that the salvianolic acid A injection preparation of the application has better safety; and the pharmacological experiments indicate that all the groups of the preparation of the application have great pharmacological effects.

The invention discloses a nano reagent based on melittin and a preparation method and an application thereof. The nano reagent is prepared by melittin, an organic dye, and hyaluronic acid. The preparation of the nano reagent is simple, hemolytic activity of melittin is greatly reduced, and the nano reagent can realize in-vivo tumour fluorescence imaging and obvious antineoplastic curative effect.The nano reagent can be effectively enriched at a tumour area after being subjected to intravenous injection in body, and can track the distribution condition of the nano reagent in the body through afluorescence signal, besides the chemotherapeutic anticancer activity of melittin, the organic dye components in the nano reagent can generate response on laser irradiation and increases the anticancer effect, so that the chemotherapy and phototherapy-combined for anticancer can be realized. In addition, the bio-security of the agent is good, the nano reagent can be widely used for preparing in-vivo cancer diagnosis and treatment-integrated medicines, and in-vivo treatment for melittin is realized.

The invention belongs to the field of antibacterial peptide and discloses an application of antibacterial peptide based on cell-penetrating peptide Tat (49-57) in the bacterium restraining aspect. The antibacterial peptide is Tat (YG) or Tat (YY) or Tat (FG) or Tat (FF), and the peptide chain sequences are sequentially shown as SEQ ID No.2, SEQ ID No.3, SEQ ID No.4 and SEQ ID No.5. The four kinds of derived antibacterial peptide have relatively good restraining efficiency for escherichia coli, salmonella typhimurium, bacillus subtilis and staphylococcus aureus, and the restraining efficiency for part of bacteria is even higher than that of the cell-penetrating peptide Tat (49-57); and moreover, the hemolytic rate of the four kinds of derived antibacterial peptide is very small, and the concentration of the four kinds of derived antibacterial peptide does not reach the lowest hemolytic concentration when the four kinds of derived antibacterial peptide achieve the antibacterial activity.

The invention discloses a vaccine adjuvant and a preparation method thereof. The vaccine adjuvant is prepared from the following components in parts by weight: water for injection, liposome, Tween-80,white oil for injection, resiquimod and Span-80. The liposome can be subjected to intramuscular injection to generate an antigen slow-release effect, and the liposome can guide antigens to antigen presenting cells to enhance the immune response of the organism. The resiquimod can promote the maturity of dendritic cells and enhance the immune response of cells and body fluid. The resiquimod playsroles depending on injection, is distributed in the whole body, is shortened in half-life period in vivo, and can not well cause adaptive immune reaction. The liposome is favorable for enabling activecomponents to pass through physiological and cellular barriers and has the advantages of enabling medicines to be targeted to the reticuloendothelial system, enhancing the medicinal effect and the like. When the liposome, the resiquimod and immunogen are used together, adaptive immune reaction caused by the resiquimod can be improved; and when the liposome and the resiquimod cooperate together, innate immune reaction can be excited, synergistic interaction can be realized, and the immune response of the organism can be improved.

The invention relates to a cortex albiziae saponin adjuvant with the effect of an immunologic adjuvant and a preparation method thereof, as well as a vaccine preparation containing the saponin adjuvant, and the application of the adjuvant and the vaccine preparation in preparing vaccine preparations. The saponin comprises cortex albiziae total saponins extracted and separated from the traditional Chinese medicine cortex albiziae, a cortex albiziae saponin adjuvant active effective part A and a cortex albiziae saponin adjuvant active effective part B, can induce local tissues to generate cytokine and chemokine, can recruit immune cells to an injection part, can induce a body to simultaneously generate Th1 and Th2 type immune responses, is capable of inducing a body to generate stronger cell immune and body fluid immune responses on the vaccine than an existing alumina gel in the prior art, can be used as an immune adjuvant of a plurality of vaccines to play a perfect immune effect. The vaccine by using the saponin as an adjuvant is simple in preparation process and method, easy in quality control and convenient to use, can be can be frozen for storage.

The invention provides a derived peptide W8 based on amphibious frog-source antibacterial peptides and a preparation method and application of the derived peptide W8. The sequence of the derived peptide W8 is shown as SEQID No.1. The preparation method comprises the following steps of designing an antibacterial peptide P8 according to the amphibious frog-source antibacterial peptides, wherein thesequence of the designed antibacterial peptide P8 is showed as AARIILRPRFR, based on the sequence, enabling No. 8 proline to be assisted with an amino acid Trp, and designing the derived peptide W8 having the sequence shown as AARIILRWRFR. The invention provides an application of the derived peptide W8 to preparation of medicines for treating diseases infected with Gram-negative bacteria, gram-positive bacteria and fungi. The bacterium-restraining activity of the antibacterial peptide W8 is obviously higher than that of Kunitzin-RE, besides, the antibacterial peptide W8 has remarkable broad spectrum bacterium-restraining activity which is not possessed by the Kunitzin-RE, and the selectivity of the antibacterial peptide W8 between bacterium cells and lactation animal cells is improved.

The invention relates to an Amolops hainanensis antimicrobial peptide Hainanenin-1, and a gene, separation purification, chemical synthesis and application thereof, belonging to the technical field of biomedicine. The Hainanenin-1 is a small peptide containing heptatomic ring at the C terminal, which is prepared by the following steps: electrically stimulating Amolops hainanensis, collecting the skin secretion, centrifuging, freeze-drying, carrying out Sephadex column chromatography and RP-HPLC (reversed phase-high performance liquid chromatography), and purifying. The molecular weight of the Hainanenin-1 is 2278.90, and the isoelectric point is 9.50. The primary structure is phenylalanine-alanine-leucine-glycine-alanine-valine-threonine-lysine-leucine-leucine-proline-serine-leucine-leucine-cysteine-methionine-isoleucine-threonine-arginine-lysine-cysteine. The precursor gene for coding the Hainanenin-1 is composed of 320 nucleotides, and the part for coding the mature peptide is 139th-201st nucleotides. When being used for preparing therapeutic drugs for pathogenic microbe infectious diseases, the Hainanenin-1 has the characteristics of broad-spectrum antimicrobial activity and low hemolysis.

The invention relates to a medicine composition containing levosimendan or the pharmaceutically acceptable salts thereof as active ingredients. The composition comprises the following ingredients: (1) 5-50mg of levosimendan or the pharmaceutically acceptable salts per dose; (2) 10-500mg of povidone K17 per dose; (3) 0.1-100ml of medicinal solvent per dose.

The invention discloses a triple peptide Cec Md3js. A nucleotide sequence for encoding the triple peptide Cec Md3js is shown as SEQ ID NO. 1, and an amino acid sequence of the triple peptide Cec Md3js is shown as SEQ ID NO. 2. An antibacterial peptide CecMd prepared by using the triple peptide Cec Md3js has antibacterial activity and high thermal stability on various bacteria, is easy to separate, purify and operate, and is suitable for large-scale industrial production. The triple peptide Cec Md3js has good application prospects in the fields of antibacterial drugs, food antibacterial agents, feed additives and the like. Moreover, the invention further provides a preparation method of the triple peptide Cec Md3js.

The invention provides a weak-acid ionizable amphiphilic zwitterionic carrier, a micelle drug delivery system and a preparation method and an application thereof. The structural general formula of theamphiphilic zwitterionic carrier is as follows: Dn-CP-TAm, wherein CP is a hydrophilic cationic polymer skeleton, and D is a zwitterionic betaine monomer; wherein n is the grafting rate of a zwitterionic betaine monomer on a hydrophilic cationic polymer skeleton, TA is a pH-sensitive monomer molecule containing a tertiary amine structure, and m is the grafting rate of the pH-sensitive monomer molecule containing the tertiary amine structure on the cationic polymer; in the weak-acid ionizable amphiphilic zwitterionic carrier, the zwitterionic betaine monomer has an in-vivo protein adsorption resisting effect and can weaken the adsorption capacity and hemolysis capacity of the cationic polymer to protein, prolong the blood circulation time of the carrier and promote accumulation of the carrier at a disease part, so that the biomacromolecule drug delivery efficiency is improved.

The invention provides a slow-release film agent of isegenan consisting of a protective layer and a medicament film layer. The invention also provides a preparation method of the film agent and an application of the film agent. The oral film agent provided by the invention not only can prolong the acting time of medicaments, guarantee the long-effect antibacterial effect of medicaments within three hours, but also can guarantee the medicament comfort for human bodies; and medicaments cannot be wasted even though the film agent is removed before a meal.

The invention relates to a progesterone water-soluble injection and a preparation method thereof. The progesterone water-soluble injection comprises progesterone, a cyclodextrin derivative solubilizer, an inclusion accelerator and injection water. Sodium citrate and citric acid are taken as the inclusion accelerator, and a complex is formed with cyclodextrin by using the polyhydric structural features of sodium citrate and citric acid, so that the inclusion constant of the complex is improved, the problem that the using amount is excessive when the progesterone water-soluble injection is prepared by using a cyclodextrin derivative as the solubilizer is solved effectively, the using amount is reduced to less than 10%, and the renal toxicity, hemolytic activity and carcinogenicity risk of the cyclodextrin derivative are reduced obviously through such using amount, so that the safety is improved. The pain reaction is relatively lower when the progesterone water-soluble injection is used for injection, the injection is low in irritation, unlikely to be allergic and high in adaptability for long-time use of a patient, and relative to clinically frequently-used progesterone oil-soluble injection in the present stage, the injection has the advantages of dosage form.

The invention provides menadione sodium bisulfite (MSB), namely a drug with the functions of preventing and treating Alzheimer's disease. It is found in research that menadione sodium bisulfite has the functions of obviously inhibiting aggregation of beta-amyloid protein1-42 (Abeta42), namely pathogenic protein of Alzheimer's disease, retarding conversion of a secondary structure of beta-amyloid protein1-42 from random coils into beta lamellas during aggregation, weakening the cytomembrane destruction capability of beta-amyloid protein1-42 toxicity congeries, inhibiting aggregation of beta-amyloid protein1-42 in cells, obviously prolonging the life of nematode in a caenorhabditis elegans AD model, achieving high safety performance and the like. It is disclosed that menadione sodium bisulfite can be applied to preparation of drugs with the functions of preventing and / or treating Alzheimer's disease.

The invention relates to a method for producing a Chinese-western compound preparation for preventing and treating animal synthetic respiratory diseases. The method comprises the following steps: (1)preparing a glycyrrhizic acid extracting solution; (2) adsorbing the glycyrrhizic acid extracting solution and an adsorbent; and (3) mixing an obtained adsorbed semi-finished product with other western medicine ingredients and auxiliary materials to obtain a finished product. The invention has the advantages that glycyrrhizic acid has the effects of tonifying middle-Jiao and Qi, clearing away heatand toxic materials, expelling phlegm and arresting cough and can also comprehensively regulate the immunity of organisms; other western medicine ingredients are combined, and the product has obviouseffects of relieving cough and eliminating phlegm so as to avoid false positive cure and also improve the concentration and the antibacterial activity of western medicine antibiotics in the respiratory system; and the product synergistically prevents and treats bacterial and viral pathogenic bacteria and has good curative effect on the animal synthetic respiratory diseases.